

**WG Annual Report. 2010-2011**  
**WG3 Cardiovascular Pharmacology and Drug Therapy**

Please find below the list of topics to be presented in your annual report.  
Every even year, the report must be submitted in July (before the ESC congress)  
Every odd year, the report must be submitted in September (after the ESC congress)

## Part 1: Identification

**Working Group on: Cardiovascular Pharmacology and Drug Therapy .....**

**Nucleus composition (precise name, surname and country):**

**CHAIRMAN:** Luis Miguel Ruilope, Madrid, Spain  
**VICE-CHAIRMAN:** Keld Per Kjeldsen. Copenhagen, Denmark  
**PAST-CHAIRMAN:** Faiez Zannad. Nancy, France  
**SECRETARY:** Maria Angeles Alonso Garcia. Madrid, Spain  
**TREASURER:** Prof. Stefan Agewall. Oslo, Norway  
**WEB EDITOR** Athul Pathak

### ORDINARY NUCLEUS MEMBERS

**Basil S. Lewis,** Israel  
**Franco Naccarella,** Italy,  
**Giuseppe M.C. Rosano,** Italy  
**Harald Schmidt.** The Netherlands  
**Sven Wassmann,** Germany

### • EX-OFFICIO MEMBERS

**Dan Atar,** Norway,  
**Kurt Stoschitzky,** Austria

## Part 2: Activities of the WG during the year

### Meetings

*(for each meeting, please precise titles, dates, places, number of participants):*

#### ▶ **WG Annual Meeting(s)**

1. Cardiovascular Trialist Forum (CVCT) Paris 2-4 December 2010. 400 participants
2. Extraordinary Nucleus Meeting  
Copenhagen. 15-17 June 2011.
3. . Nucleus Position Paper Meetings:  
Copenhagen. 30-31 March 2011.

#### ▶ **Endorsed Meeting**

1. European Meeting on Hypertension and Cardiovascular Prevention. June 17-21 2011.  
Milan.

#### ▶ **Education programme(s)**

1. Conference on Cardiac Arrest and Sudden Death – Cardiovascular Therapy.  
Copenhagen. 16-18 June 2011. N° Participants 300

## Papers & Guidelines

(for papers and publications, please precise titles, authors and journal/issue where the paper is published)

▶ Publications & Scientific Papers *submitted by the WG, not by individuals*)

1. Ultrasound and Radiology surrogate end-points in pharmacological studies. Stefan Agewall. Submitted to the Eur Heart J.
2. Risk stratification in cardiovascular disease primary prevention – how will novel markers and imaging techniques add to current risk scoring systems? Accepted on the European Journal of Cardiovascular Prevention & Rehabilitation. Faiez
3. Risk-guided therapy for cardiovascular disease primary prevention – challenges and opportunities for practical implementation. Accepted on the European Journal of Cardiovascular Prevention & Rehabilitation Faiez

▶ Guideline participation (writing or reviewing)

1. 2011. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Stefan Agewall, Member of the Task Force
2. 2011 ESC Guidelines on the management of cardiovascular diseases during pregnancy. Angeles Alonso -García, Reviewer
3. 2011. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases. Stefan Agewall and Luis Miguel Ruilope. Reviewers
4. 2011 ESC/EAS Guidelines for the management of dyslipidaemias. Stefan Agewall, Member of the Task Force. Giuseppe Rosano, Reviewer
- 5 Guidelines for the Management of Acute Coronary Syndromes in patients presenting without ST-Segment elevation (NSTEMI-ACS) Keld Kjeldsen. Reviewer

▶ WG officially affiliated to a journal? Which one?

European Heart Journal accepted to renew the affiliation of the Journal "Fundamental and Clinical Pharmacology " with the ESC and the Publications Committee in particular (continuation of our affiliation in 2012)

## Sessions

(for sessions, please precise titles and accepted/rejected status):

▶ Proposals for pre-arranged sessions at the ESC main congress and/or ESC Sub-specialty meetings

A. ESC 2011 Congress Paris

1. Are there geographical variations in outcome trials?
2. The myth of class effects
3. Controversial issues in diabetes management
4. Controversies in acute coronary syndrome
5. Autonomic nervous system and humoral regulations

▶ Task Force(s)

▶ Registry / Survey

1. EURObservational Research Programme of the ESC. Ongoing Registries. 2011 ESC Congress Paris

▶ Accreditation programme

### Part 3:

- ▶ List your future projects / business plan

**Position Papers:** Three under discussion:

1. What is the optimum potassium concentration and how to ensure it? Keld
2. Beta-blockers in Acute Coronary Syndromes without left ventricular: Dan and Kurt
3. Pharmacological reasons to explain why randomized clinical trials failed in acute heart failure syndromes (with HF Association)

**Next Meetings**

1. CVCT 2-3 December. Paris. 2011
2. Joint Session in the Annual Meeting of the European Society of Hypertension. 7-9 Marzo 2012. Madrid
3. Cardiovascular Spring Summit. June 2012 Vienna

**Projects**

Work in association with the European Clinical Pharmacology Society (to recruit more WG members and future sessions and meetings)

Active Participation with Joint sessions in the 2012 ESC Congress

Active Participation in ongoing ESC Clinical Guidelines

- ▶ Prepare your budget for 2011-2012 (see sample) List your Income:  
ESC grant PP meeting 10 000  
ESC grant extra nucleus meeting 10 000  
CBSC donation 2000
- ▶ List your main expenses:  
Expenses are the corresponding meeting costs